Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2015

01.06.2015 | short review

The role of positron emission tomography in breast cancer: a short review

verfasst von: MD Maria Adele Marino, MD, MSc, MBA Univ. Prof. Thomas H. Helbich, MD Univ. Prof. Alfredo Blandino, MD, EBBI Assoc. Prof. Katja Pinker

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Positron emission tomography (PET) provides information about abnormal metabolic features associated with cancer, and its role in breast cancer has been widely investigated. In the past several years, combined imaging systems, such as PET/CT and PET/MRI, and dedicated breast PET devices, such as PEM and MAMMI-PET, have been developed and implemented. These new techniques have become an effective oncologic tool for staging, re-staging, monitoring response to treatment, and estimation of the long-term prognosis. The aim of this review is to summarize the established and emerging PET imaging techniques and to discuss their value in the management of breast cancer patients.
Literatur
1.
Zurück zum Zitat Malvezzi M, Bertuccio P, Rosso T, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;26:779–86. doi:10.1093/annonc/mdv001. Malvezzi M, Bertuccio P, Rosso T, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;26:779–86. doi:10.1093/annonc/mdv001.
2.
Zurück zum Zitat Bosetti C, Bertuccio P, Levi F, et al. The decline in breast cancer mortality in Europe: an update (to 2009). Breast. 2012;21:77–82. PubMedCrossRef Bosetti C, Bertuccio P, Levi F, et al. The decline in breast cancer mortality in Europe: an update (to 2009). Breast. 2012;21:77–82. PubMedCrossRef
3.
Zurück zum Zitat Carlson RW, Allred DC, Anderson BO, et al. Invasive breast cancer. J Natl Compr Canc Netw. 2011;9:136–222. PubMed Carlson RW, Allred DC, Anderson BO, et al. Invasive breast cancer. J Natl Compr Canc Netw. 2011;9:136–222. PubMed
4.
Zurück zum Zitat Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46(8):1296–316. PubMedCrossRef Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46(8):1296–316. PubMedCrossRef
5.
Zurück zum Zitat Pinker K, Bogner W, Baltzer P, Gruber S, Bickel H, Brueck B, et al. Improved diagnostic accuracy with multiparametric magnetic resonance imaging of the breast using dynamic contrast-enhanced magnetic resonance imaging, diffusion-weighted imaging, and 3-dimensional proton magnetic resonance spectroscopic imaging. Invest Radiol. 2014;49(6):421–30. PubMedCrossRef Pinker K, Bogner W, Baltzer P, Gruber S, Bickel H, Brueck B, et al. Improved diagnostic accuracy with multiparametric magnetic resonance imaging of the breast using dynamic contrast-enhanced magnetic resonance imaging, diffusion-weighted imaging, and 3-dimensional proton magnetic resonance spectroscopic imaging. Invest Radiol. 2014;49(6):421–30. PubMedCrossRef
6.
Zurück zum Zitat Pinker K, Bogner W, Baltzer P, Karanikas G, Magometschnigg H, Brader P, et al. Improved differentiation of benign and malignant breast tumors with multiparametric 18fluorodeoxyglucose positron emission tomography magnetic resonance imaging: a feasibility study. Clin Cancer Res. 2014;20(13):3540–9. doi:10.1158/1078-0432.CCR-13-2810. Pinker K, Bogner W, Baltzer P, Karanikas G, Magometschnigg H, Brader P, et al. Improved differentiation of benign and malignant breast tumors with multiparametric 18fluorodeoxyglucose positron emission tomography magnetic resonance imaging: a feasibility study. Clin Cancer Res. 2014;20(13):3540–9. doi:10.1158/1078-0432.CCR-13-2810.
7.
Zurück zum Zitat Baltzer PA, Dietzel M. Breast lesions: diagnosis by using proton MR spectroscopy at 1.5 and 3.0 T—systematic review and meta-analysis. Radiology. 2013;267(3):735–46. Baltzer PA, Dietzel M. Breast lesions: diagnosis by using proton MR spectroscopy at 1.5 and 3.0 T—systematic review and meta-analysis. Radiology. 2013;267(3):735–46.
8.
Zurück zum Zitat Kong EJ, Chun KA, Bom HS, Lee J, Lee SJ, Cho IH. Initial experience of integrated PET/MR mammography in patients with invasive ductal carcinoma. Hell J Nucl Med. 2014;17(3):171–6. PubMed Kong EJ, Chun KA, Bom HS, Lee J, Lee SJ, Cho IH. Initial experience of integrated PET/MR mammography in patients with invasive ductal carcinoma. Hell J Nucl Med. 2014;17(3):171–6. PubMed
9.
Zurück zum Zitat Warburg O. Metabolism of tumors. London:constable and Company; 1930. Warburg O. Metabolism of tumors. London:constable and Company; 1930.
10.
Zurück zum Zitat Groheux D, Espié M, Giacchetti S, Hindié E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013;266(2):388–405. doi:10.1148/radiol.12110853. Groheux D, Espié M, Giacchetti S, Hindié E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013;266(2):388–405. doi:10.1148/radiol.12110853.
11.
Zurück zum Zitat Avril N, Rosé CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18(20):3495–502. PubMed Avril N, Rosé CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18(20):3495–502. PubMed
12.
Zurück zum Zitat Kalles V, Zografos GC, Provatopoulou X, et al. The current status of positron emission mammography in breast cancer. Breast Cancer. 2013;20(2):123–30. PubMedCrossRef Kalles V, Zografos GC, Provatopoulou X, et al. The current status of positron emission mammography in breast cancer. Breast Cancer. 2013;20(2):123–30. PubMedCrossRef
13.
Zurück zum Zitat Yoon H, Kang KW, Chun IK, Cho N, et al. Correlation of breast cancer subtypes, based on estrogen receptor, progesteron receptor, and HER2 with functional imaging parameters from 68GA-RDG PET/CT and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2014;41:1534–43. PubMedCrossRef Yoon H, Kang KW, Chun IK, Cho N, et al. Correlation of breast cancer subtypes, based on estrogen receptor, progesteron receptor, and HER2 with functional imaging parameters from 68GA-RDG PET/CT and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2014;41:1534–43. PubMedCrossRef
14.
Zurück zum Zitat Mavi A, Urhan M, Yu JQ, et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47(9):1440–6. PubMed Mavi A, Urhan M, Yu JQ, et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47(9):1440–6. PubMed
15.
Zurück zum Zitat Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242:360–85. PubMedCrossRef Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242:360–85. PubMedCrossRef
16.
Zurück zum Zitat Berg WA, Madsen KS, Schilling K, et al. Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer. AJR Am J Roentgenol. 2012;198:219–32. PubMedCrossRef Berg WA, Madsen KS, Schilling K, et al. Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer. AJR Am J Roentgenol. 2012;198:219–32. PubMedCrossRef
17.
Zurück zum Zitat Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, et al. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012;83:1381–6. PubMedCrossRef Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, et al. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012;83:1381–6. PubMedCrossRef
18.
Zurück zum Zitat Park JS, Moon WK, Lyou CY, Cho N, Kang KW, Chung JK. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emmision tomography. Acta Radiol. 2011;52(1):21–8. Park JS, Moon WK, Lyou CY, Cho N, Kang KW, Chung JK. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emmision tomography. Acta Radiol. 2011;52(1):21–8.
19.
Zurück zum Zitat Tatsumi M, Cohade C, Mourtzikos KA, et al. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. 2006;33(3):254–62. PubMedCrossRef Tatsumi M, Cohade C, Mourtzikos KA, et al. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. 2006;33(3):254–62. PubMedCrossRef
20.
Zurück zum Zitat Rosen EL, Eubank W, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27:S215–29. Rosen EL, Eubank W, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27:S215–29.
21.
Zurück zum Zitat Magometschnigg HF, Helbich TH, Brader P, et al. Molecular imaging for the characterization of breast tumours. Expert Rev Anticancer Ther. 2014;14(6):711–22. PubMedCrossRef Magometschnigg HF, Helbich TH, Brader P, et al. Molecular imaging for the characterization of breast tumours. Expert Rev Anticancer Ther. 2014;14(6):711–22. PubMedCrossRef
22.
Zurück zum Zitat Choi YJ, Shin YD, Kang YH, et al. The effects of preoperative (18)F-FDG PET/CT in breast cancer patients in comparison to the conventional imaging study. J Breast Cancer. 2012;15(4):441–8. PubMedCentralPubMedCrossRef Choi YJ, Shin YD, Kang YH, et al. The effects of preoperative (18)F-FDG PET/CT in breast cancer patients in comparison to the conventional imaging study. J Breast Cancer. 2012;15(4):441–8. PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Taneja S, Jena A, Goel R, Sarin R, et al. Simultaneous whole-body 18F-FDG PET/MRI in primary staging of breast cancer: a pilot study. Eur J Radiol. 2014;83:2231–9. PubMedCrossRef Taneja S, Jena A, Goel R, Sarin R, et al. Simultaneous whole-body 18F-FDG PET/MRI in primary staging of breast cancer: a pilot study. Eur J Radiol. 2014;83:2231–9. PubMedCrossRef
24.
Zurück zum Zitat Pinker K, Bickel H, Magometschnigg H, et al. Molecular imaging of breast tumours with PET/MRI—proof of concept. 6th EMIM. 2011;8:92. Pinker K, Bickel H, Magometschnigg H, et al. Molecular imaging of breast tumours with PET/MRI—proof of concept. 6th EMIM. 2011;8:92.
25.
Zurück zum Zitat Eo JS, Chun IK, Paeng JC, et al. Imaging sensitivity of dedicated positron emission mammography in relation to tumour size. Breast. 2012;21(1):66–71. doi:10.1016/j.breast.2011.08.002. Epub 2011 Aug 25. PubMedCrossRef Eo JS, Chun IK, Paeng JC, et al. Imaging sensitivity of dedicated positron emission mammography in relation to tumour size. Breast. 2012;21(1):66–71. doi:10.1016/j.breast.2011.08.002. Epub 2011 Aug 25. PubMedCrossRef
26.
Zurück zum Zitat Mankoff DA, Sprecht JM. [18F]Fluorodeoxyglucose positron emission tomography—computed tomography in breast cancer: when… and when not? J Clin Oncol. 2012;30(12):1252–4. PubMedCrossRef Mankoff DA, Sprecht JM. [18F]Fluorodeoxyglucose positron emission tomography—computed tomography in breast cancer: when… and when not? J Clin Oncol. 2012;30(12):1252–4. PubMedCrossRef
27.
Zurück zum Zitat Koolen BB, Vogel WV, Vrancken Peeters MJTFD, et al. Molecular imaging in breast cancer: from whole-body PET/CT to dedicated breast PET. J Oncol. 2012. doi:10.1155/2012/438647. Koolen BB, Vogel WV, Vrancken Peeters MJTFD, et al. Molecular imaging in breast cancer: from whole-body PET/CT to dedicated breast PET. J Oncol. 2012. doi:10.1155/2012/438647.
28.
Zurück zum Zitat Riedl CC, Slobod E, Jochelson M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014;55(10):1578–83. PubMedCentralPubMedCrossRef Riedl CC, Slobod E, Jochelson M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014;55(10):1578–83. PubMedCentralPubMedCrossRef
Metadaten
Titel
The role of positron emission tomography in breast cancer: a short review
verfasst von
MD Maria Adele Marino
MD, MSc, MBA Univ. Prof. Thomas H. Helbich
MD Univ. Prof. Alfredo Blandino
MD, EBBI Assoc. Prof. Katja Pinker
Publikationsdatum
01.06.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0210-z